As the accumulation of deleterious mutations should adversely impact the fitness of a tumour (67), we were intrigued why an increased mutation rate is apparently selected for in prostate cancer via hypermethylation of GSTP1 and GSTM2. This evidence concerns the gene GSTP1 and neoplasm.